2020-005633-33: Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine |
|
|
| Not yet recruiting | 4 | 100 | Europe | Rivastigmine, Transdermal patch, Rivastigmine | University Medical Center Groningen, Netherlands Organization for Scientific Research | A depressive disorder, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003219-23: CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease) |
|
|
| Not yet recruiting | 3 | 600 | Europe | Rivastigmin Luye Transdermal Patches - 4.6mg/24h, Rivastigmine Luye Transdermal Patch- 9.5mg/24h, Rivastigmine transdermal system 13.3 mg/24 h, N/A, RIV-TDS 13.3 mg/24 h, Transdermal patch, Rivastigmin Luye Transdermal Patches - 4.6mg/24h, Rivastigmine Luye Transdermal Patch- 9.5mg/24h | University of Bristol, National Institute for Health Research, Health Assessment Technology Programme | This trial will investigate the effectiveness of Rivastigmine on prevention of falls in patients with Parkinson's disease, Parkinson's Disease is a condition in which the nervous system is damaged which leads to a loss of control of the muscles that control walking and balance., Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT05853341: Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h) |
|
|
| Completed | 1 | 48 | Europe | RID-TDS 13.3 mg/24 h, Exelon® 13.3 mg/24 h | Luye Pharma Group Ltd., SocraTec R&D GmbH, SocraMetrics GmbH | Healthy | 07/23 | 07/23 | | |